Table2_Oral Curcumin With Piperine as Adjuvant Therapy for the Treatment of COVID-19: A Randomized Clinical Trial.pdf
Background: Coronavirus disease-2019 (COVID-19) has a wide range of pathophysiological effects. Curcumin, an active constituent of Curcuma longa (turmeric), has several properties, including anti-inflammatory, antioxidant, antiviral, anti-thrombotic, and anti-proliferative effects, which make it a promising candidate for the symptomatic treatment of COVID-19.
Objective: We aimed to determine the effects of curcumin administered with piperine (to optimize absorption) on symptoms in patients with COVID-19 in a double-blind, randomized, controlled trial at a 30-bed dedicated COVID Health Center (DCHC) in Maharashtra, India.
Methods: In addition to conventional COVID-19 treatment, patients in the control group received a dose of probiotics twice a day, and patients in the study group received curcumin (525 mg) with piperine (2.5 mg) in tablet form twice a day. The effects of curcumin/piperine treatment on primary and secondary outcomes were assessed for the duration of hospitalization.
Results: Patients with mild, moderate, and severe symptoms who received curcumin/piperine treatment showed early symptomatic recovery (fever, cough, sore throat, and breathlessness), less deterioration, fewer red flag signs, better ability to maintain oxygen saturation above 94% on room air, and better clinical outcomes compared to patients of the control group. Furthermore, curcumin/piperine treatment appeared to reduce the duration of hospitalization in patients with moderate to severe symptoms, and fewer deaths were observed in the curcumin/piperine treatment group.
Conclusions: Administration of oral curcumin with piperine as an adjuvant symptomatic therapy in COVID-19 treatment could substantially reduce morbidity and mortality, and ease the logistical and supply-related burdens on the healthcare system. Curcumin could be a safe and natural therapeutic option to prevent Post-Covid thromboembolic events.
Clinicaltrials.gov identifier:CTRI/2020/05/025482
History
References
- https://doi.org//10.1016/j.biocel.2008.06.010
- https://doi.org//10.1021/mp700113r
- https://doi.org//10.1002/mnfr.200700259
- https://doi.org//10.23812/20-34-4EDIT-65
- https://doi.org//10.1016/j.jff.2017.12.015
- https://doi.org//10.3390/molecules191220139
- https://doi.org//10.1208/s12248-012-9432-8
- https://doi.org//10.1517/17425255.2011.570332
- https://doi.org//10.3390/foods6100092
- https://doi.org//10.1016/S0140-6736%2820%2930183-5
- https://doi.org//10.1002/jcp.26249
- https://doi.org//10.5483/bmbrep.2012.45.4.221
- https://doi.org//10.13005/bpj/1555
- https://doi.org//10.3389/fcell.2020.00479
- https://doi.org//10.1007/s13337-020-00598-8
- https://doi.org//10.1080/10408398.2017.1358139
- https://doi.org//10.1254/jphs.10126sc
- https://doi.org//10.1016/s0140-6736%2800%2998193-5
- https://doi.org//10.1586/14737175.8.8.1175
- https://doi.org//10.1371/journal.pone.0215840
- https://doi.org//10.1208/s12248-009-9128-x
- https://doi.org//10.1016/j.ejmech.2018.12.016
- https://doi.org//10.3390/molecules20022728
- https://doi.org//10.1111/j.1365-2249.2006.03257.x
- https://doi.org//10.1358/mf.2010.32.4.1452090
- https://doi.org//10.1055/s-2006-957450
- https://doi.org//10.21467/preprints.213
- https://doi.org//10.1007/s12291-020-00914-5
- https://doi.org//10.14200/jrm.2017.6.0101
- https://doi.org//10.1007/978-0-387-46401-5_17
- https://doi.org//10.1016/j.ijcard.2009.01.073
- https://doi.org//10.1002/ptr.6738
- https://doi.org//10.1155/2013/636053
CC BY 4.0